Zogenix, Inc. (Zogenix) is a pharmaceutical company. The Company commercializes and develops products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate), an agonist, is used for the treatment of chronic pain requiring opioid therapy. The Company completed Phase III development of Zohydro in 2011. Zogenix’s second DosePro investigational product candidate, Relday, is an injectable formulation of risperidone for the treatment of schizophrenia. This trial was a randomized, 12-week, double-blind, placebo-controlled to evaluate the efficacy of Zohydro ER for the treatment of moderate to severe chronic lower back pain in opioid-experienced adult subjects. The Company also commercializes Sumavel DosePro, a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache and is approved by the Food and Drug Administration (FDA).